Xalkori (crizotinib) vs Lumakras (sotorasib)

Xalkori (crizotinib) and Lumakras (sotorasib) are both targeted therapies used to treat certain types of cancer, but they are indicated for different genetic mutations. Xalkori is typically prescribed for patients with advanced non-small cell lung cancer (NSCLC) that is ALK or ROS1-positive, as it inhibits these specific proteins to slow the growth of cancer cells. On the other hand, Lumakras is approved for use in patients with NSCLC who have a specific mutation known as KRAS G12C and have received at least one prior systemic therapy; it works by directly targeting the KRAS G12C mutation. Patients should consult with their healthcare provider to determine which medication is appropriate for their specific genetic mutation and treatment history.

Difference between Xalkori and Lumakras

Metric	Xalkori (crizotinib)	Lumakras (sotorasib)
Generic name	Crizotinib	Sotorasib
Indications	Non-small cell lung cancer (NSCLC), ALK-positive and ROS1-positive	Non-small cell lung cancer (NSCLC), KRAS G12C-mutated
Mechanism of action	ALK and ROS1 tyrosine kinase inhibitor	KRAS G12C inhibitor
Brand names	Xalkori	Lumakras
Administrative route	Oral	Oral
Side effects	Visual disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, neuropathy	Diarrhea, musculoskeletal pain, nausea, fatigue, liver damage, cough, abdominal pain
Contraindications	Hepatic impairment, concurrent use with strong CYP3A inhibitors or inducers	Hepatic impairment, severe renal impairment
Drug class	Tyrosine kinase inhibitor	Protein kinase inhibitor
Manufacturer	Pfizer	Amgen

Efficacy

Xalkori (Crizotinib) Efficacy in Lung Cancer

Xalkori (crizotinib) is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. The efficacy of crizotinib has been demonstrated in clinical trials where it has shown significant improvement in progression-free survival compared to chemotherapy in patients with ALK-positive NSCLC. In these studies, patients treated with crizotinib experienced a longer duration of time without disease progression, highlighting its role as an effective first-line treatment option for this specific subgroup of lung cancer patients.

Crizotinib has also been shown to have activity against tumors that harbor ROS1 rearrangements, another genetic alteration found in a small percentage of lung cancer patients. Clinical trials have reported high response rates in patients with ROS1-positive NSCLC, further establishing crizotinib's efficacy in targeting specific genetic drivers of lung cancer. The precision of crizotinib's mechanism of action allows for a more personalized approach to lung cancer treatment, which can lead to better outcomes for patients with these genetic profiles.

Lumakras (Sotorasib) Efficacy in Lung Cancer

Lumakras (sotorasib) is a novel medication that has been granted accelerated approval by the FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy. This approval is based on the positive results from a phase 2 clinical trial, which demonstrated a significant objective response rate in patients with the KRAS G12C mutation. Sotorasib specifically targets the KRAS G12C mutation, which is present in approximately 13% of patients with NSCLC, making it a promising targeted therapy for this subset of lung cancer patients.

The clinical trial data for sotorasib has shown a durable response and disease control in patients with KRAS G12C-mutated NSCLC, indicating that it can be an effective treatment option after the failure of prior therapies. The introduction of sotorasib provides a new line of defense against lung cancer and represents a milestone in the development of treatments targeting previously 'undruggable' mutations. As the first FDA-approved KRAS inhibitor, sotorasib's efficacy marks a significant advancement in the personalized treatment landscape for lung cancer.

Regulatory Agency Approvals

Xalkori

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia

Lumakras

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Medicines & Healthcare products Regulatory Agency (MHRA), United Kingdom

Access Xalkori or Lumakras today

If Xalkori or Lumakras are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Xalkori

Buy Lumakras

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: